Information Provided By: 
Fly News Breaks for May 6, 2019
RARE
May 6, 2019 | 20:29 EDT
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $75 price target on Ultragenyx, saying its Q1 results were "fairly in-line" amid continued momentum for its Crysvita program. The analyst is also positive on the "significant news flow" expected for Ultragenyx this year, which includes the U.S. regulatory filing for its UX007 and key gene therapy assets data.
News For RARE From the Last 2 Days
